lapatinib has been researched along with imatinib mesylate in 18 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (imatinib mesylate) | Trials (imatinib mesylate) | Recent Studies (post-2010) (imatinib mesylate) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 11,477 | 960 | 5,773 |
| Protein | Taxonomy | lapatinib (IC50) | imatinib mesylate (IC50) |
|---|---|---|---|
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 0.31 | |
| Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | 0.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 11 (61.11) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Boyle, SN; Koleske, AJ | 1 |
| Giordano, S; Petrelli, A | 1 |
| Caldara, A; Graiff, C; Mandarà, M; Pedersini, R; Sava, T; Vattemi, E | 1 |
| Decosterd, LA; Duchosal, MA; Haouala, A; Leyvraz, S; Montemurro, M; Ris, HB; Rochat, B; Widmer, N; Zaman, K; Zanolari, B | 1 |
| Gelderblom, H; Guchelaar, HJ; van Erp, NP | 1 |
| Ho, PC; Lo, YH; Wang, SC; Zhao, H | 1 |
| Bristow, RG; Groselj, B; Kerr, M; Kiltie, AE; Knowles, MA; Phillips, RM; Qiao, B; Teo, MT | 1 |
| Andriamanana, I; Duretz, B; Gana, I; Hulin, A | 1 |
| Andrianifahanana, M; Becker, J; Edens, M; Gupta, SK; Leof, EB; Maidl, E; Rahimi, RA; Repellin, CE; Wilkes, MC; Wittenberger, J; Yin, X | 1 |
| Ashby, CR; Chen, ZS; Kathawala, RJ; Wang, YJ | 1 |
| Behera, R; Mensa-Wilmot, K; Thomas, SM | 1 |
| Bower, M; Erbacher, I; Fortunak, J; Gotham, D; Hill, A; Levi, J; Martin, M; Meldrum, J; Powderly, WG; Shoman, H | 1 |
| Broutin, S; Gil, S; Jovelet, C; Mir, O; Paci, A | 1 |
| Adam, T; Bouchalová, K; Faber, E; Friedecký, D; Janečková, H; Mičová, K; Vrobel, I | 1 |
| Griffith, N; Kolli, S; Li, Q; Liu, Z; Poi, MJ; Wetz, K | 1 |
| Kim, HS; Kim, JY; Yoon, S | 1 |
| Cheng, Q; Feng, F; Han, M; Jiang, X; Li, B; Li, F; Li, JY; Li, Z; Liu, C; Qin, H; Qiu, Z; Xiong, L; Xu, C; Yi, B; Yu, Y; Zhang, D | 1 |
| Ito, Y; Kondo, M; Koseki, T; Tanaka, J; Yamada, S | 1 |
6 review(s) available for lapatinib and imatinib mesylate
| Article | Year |
|---|---|
Dissecting kinase signaling pathways.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Drug Delivery Systems; Humans; Imatinib Mesylate; Lapatinib; Neoplasms; Phosphoproteins; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Pyrimidines; Quinazolines; Signal Transduction; Trastuzumab | 2007 |
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Bevacizumab; Cetuximab; Clinical Trials as Topic; Enzyme Inhibitors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib; Trastuzumab | 2008 |
Systemic therapies for recurrent and/or metastatic salivary gland cancers.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Boronic Acids; Bortezomib; Cetuximab; Gefitinib; Humans; Imatinib Mesylate; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Piperazines; Pyrazines; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Trastuzumab | 2008 |
Clinical pharmacokinetics of tyrosine kinase inhibitors.
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Benzenesulfonates; Biological Availability; Cytochrome P-450 Enzyme System; Dasatinib; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Intestinal Absorption; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; Tissue Distribution | 2009 |
Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs.
Topics: Antineoplastic Agents; Benzamides; Benzylisoquinolines; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Imidazoles; Lapatinib; Multidrug Resistance-Associated Proteins; Piperazines; Purines; Pyrimidines; Quinazolines; Sildenafil Citrate; Sulfonamides; Sulfones; Taxoids; Triazines; Vardenafil Dihydrochloride | 2014 |
[Tyrosine kinase inhibitors and pregnancy: A risk to the fetus?].
Topics: Abnormalities, Drug-Induced; Adult; Antineoplastic Agents; Dasatinib; Erlotinib Hydrochloride; Female; Fetus; Gefitinib; Humans; Imatinib Mesylate; Lapatinib; Maternal Age; Placenta; Pregnancy; Pregnancy Complications, Neoplastic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Risk | 2016 |
12 other study(ies) available for lapatinib and imatinib mesylate
| Article | Year |
|---|---|
Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Chromatography, Liquid; Dasatinib; Drug Monitoring; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles | 2009 |
Inhibition of c-ABL sensitizes breast cancer cells to the dual ErbB receptor tyrosine kinase inhibitor lapatinib (GW572016).
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Female; Gene Knockdown Techniques; Humans; Imatinib Mesylate; Lapatinib; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2011 |
Imatinib radiosensitizes bladder cancer by targeting homologous recombination.
Topics: Antigens, Nuclear; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Survival; DNA-Binding Proteins; Homologous Recombination; Humans; Imatinib Mesylate; Ku Autoantigen; Lapatinib; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Rad51 Recombinase; Radiation-Sensitizing Agents; RNA Interference; Urinary Bladder Neoplasms | 2013 |
Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.
Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Chromatography, Liquid; Dasatinib; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Pyrazines; Pyrimidines; Pyrroles; Quinazolines; Reproducibility of Results; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles | 2013 |
Profibrotic TGFβ responses require the cooperative action of PDGF and ErbB receptor tyrosine kinases.
Topics: Animals; Benzamides; Bleomycin; Cell Line; Drug Interactions; Epidermal Growth Factor; ErbB Receptors; Feedback, Physiological; Imatinib Mesylate; Lapatinib; Lung; Mice; Myofibroblasts; Paracrine Communication; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pulmonary Fibrosis; Pulmonary Gas Exchange; Pyrimidines; Quinazolines; Receptor, ErbB-2; Receptors, Platelet-Derived Growth Factor; Transforming Growth Factor beta; Up-Regulation | 2013 |
New chemical scaffolds for human african trypanosomiasis lead discovery from a screen of tyrosine kinase inhibitor drugs.
Topics: Animals; Axitinib; Benzamides; Erlotinib Hydrochloride; Female; HeLa Cells; Humans; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lapatinib; Mice; Morpholines; Piperazines; Protein Kinase Inhibitors; Purines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Trypanosomiasis, African | 2014 |
Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment.
Topics: Antineoplastic Agents; Commerce; Drug Industry; Erlotinib Hydrochloride; Global Health; Humans; Imatinib Mesylate; Lapatinib; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Sorafenib | 2016 |
Ultrafast Online SPE-MS/MS Method for Quantification of 3 Tyrosine Kinase Inhibitors in Human Plasma.
Topics: Calibration; Chromatography, Liquid; Drug Monitoring; Humans; Imatinib Mesylate; Lapatinib; Plasma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Reproducibility of Results; Solid Phase Extraction; Tandem Mass Spectrometry | 2016 |
Stability of extemporaneous erlotinib, lapatinib, and imatinib oral suspensions.
Topics: Administration, Oral; Chemistry, Pharmaceutical; Dosage Forms; Drug Stability; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Lapatinib; Quinazolines; Suspensions | 2016 |
Tyrosine Kinase Inhibitors Imatinib and Erlotinib Increase Apoptosis of Antimitotic Drug-resistant KBV20C Cells Without Inhibiting P-gp.
Topics: Antimitotic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Lapatinib; Protein Kinase Inhibitors; Vincristine | 2019 |
Targeted deep sequencing contributes to guiding personalized targeted therapy for advanced biliary tract cancer patients with non‑radical resection: A real‑world study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Class I Phosphatidylinositol 3-Kinases; Dasatinib; Deoxycytidine; ErbB Receptors; Everolimus; Female; Gemcitabine; Genes, Neoplasm; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Lapatinib; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Organoplatinum Compounds; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Survival Rate; Treatment Outcome | 2020 |
Analyses of Ocular Adverse Reactions Associated With Anticancer Drugs Based on the Japanese Pharmacovigilance Database.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Imatinib Mesylate; Japan; Lapatinib; Pharmacovigilance; Tamoxifen | 2022 |